EFFEOTivENEss of modern antiviral therapy iN lipid DisTREss syndrome iN patients with chronic hepatitis c


Cite item

Full Text

Abstract

This article is devoted to studying of the effectiveness of modern antiviral therapy with direct antiviral drugs (sofos-buvirom and daklatasvirom) in patients with chronic hepatitis С and lipidic distress syndrome. The study shows the effectiveness of treatment in this category patients to accounted for 84,4%. Reduced effectiveness of antiviral therapy with sofosbuvirom and daklatasvirom was revealed in 12,6% as compared to the group of patients with chronic hepatitis С. It was has been associated with the development of dyslipidemia, the severity of which increased with the progression of liver fibrosis. Drugs of direct antiviral activity (sofosbuvir + daklatasvir) in patients with the first stage of fibrosis (F1) decreased dyslipidemia, and in patients with the second and third stage (F2 and F3) they cause increase in haemoglobin that can deteriorate condition of target organs in case of lipid distress syndrome in patients with chronic hepatitis С and the proression of liver fibrosis.

About the authors

D Yu Konstantinov

Samara State Medical University

Email: dk.samgmu@mail.ru
Candidate of Medicine, Associate Professor, Department of Infectious Diseases with the Course of Epidemiology

References

  1. Петухов В.А., Кириенко А.И., Сафонов М.В. Способ диагностики атеросклероза. Патент РФ № 2093077 от 20.10.1997
  2. Савельев В.С., Петухов В.А., Каралкин А.В. Способ диагностики диффузного жирового гепатоза. Патент РФ № 2204327 от 20.05.2003
  3. Савельев В.С., Яблоков Е.Г., Петухов В.А. Способ диагностики хронической ишемической болезни органов пищеварения. Патент РФ № 2145189 от 20.07.2005
  4. Яблоков Е.Г. Петухов В.А., Куликов В.М. Способ диагностики холестероза желчного пузыря. Патент РФ № 2144788 от 27.01.2000
  5. Fattovic G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cir-rhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35-50
  6. Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter. 2013;164(4):305-312. doi: 10.7417/CT.2013.1594
  7. Gentile I, Borgia G. Surrogate endpoints and noninferiority trials in chronic viral hepatitis. J Hepatol. 2010;52(5):778. doi: 10.1016/j.jhep.2009.12.023
  8. oofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(3 Suppl 1):15S-20S. doi: 10.1002/hep.510260703
  9. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401-412. doi: 10.1016/j. bpg.2012.09.009
  10. Sagnelli E, Pisaturo M, Stanzione M, et al. Clinical presentation, outcome, and response to therapyamong patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11(9):1174-1180
  11. Takahashi K, Nishida N, Kawabata H, et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med. 2012;51(19):2745-2747

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Konstantinov D.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).